A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
NCT ID: NCT06294301
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
68 participants
INTERVENTIONAL
2023-11-23
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults
NCT06326814
Study to Evaluate LPH-5 in Healthy Subjects
NCT06722820
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
NCT05095168
Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects
NCT04217629
Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers
NCT05462132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: LP-005 Dose 1 (Single)
LP-005 Dose 1 (Single)
A single dose of LP-005 (Dose 1) was administered intravenously.
Cohort 2: LP-005 Dose 2 (Single)
LP-005 Dose 2 (Single)
A single dose of LP-005 (Dose 2) was administered intravenously.
Cohort 3: LP-005 Dose 3 (Single)
LP-005 Dose 3 (Single)
A single dose of LP-005 (Dose 3) was administered intravenously.
Cohort 4: LP-005 Dose 4 (Single)
LP-005 Dose 4 (Single)
A single dose of LP-005 (Dose 4) was administered intravenously.
Cohort 5: LP-005 Dose 5 (Single)
LP-005 Dose 5 (Single)
A single dose of LP-005 (Dose 5) was administered intravenously.
Cohort 6: LP-005 Dose 6 (Single)
LP-005 Dose 6 (Single)
A single dose of LP-005 (Dose 6) was administered intravenously.
Cohort 7: Placebo (Single)
Placebo (Single)
A single dose of placebo was administered intravenously.
Cohort 8: LP-005 Dose 7 (Multiple)
LP-005 Dose 7 (Multiple)
LP-005 (Dose 7) was administered multiple times intravenously.
Cohort 9: LP-005 Dose 8 (Multiple)
LP-005 Dose 8 (Multiple)
LP-005 (Dose 8) was administered multiple times intravenously.
Cohort 10: LP-005 Dose 9 (Multiple)
LP-005 Dose 9 (Multiple)
LP-005 (Dose 9) was administered multiple times intravenously.
Cohort 11: Placebo (Multiple)
Placebo (Multiple)
Placebo was administered multiple times intravenously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LP-005 Dose 1 (Single)
A single dose of LP-005 (Dose 1) was administered intravenously.
LP-005 Dose 2 (Single)
A single dose of LP-005 (Dose 2) was administered intravenously.
LP-005 Dose 3 (Single)
A single dose of LP-005 (Dose 3) was administered intravenously.
LP-005 Dose 4 (Single)
A single dose of LP-005 (Dose 4) was administered intravenously.
LP-005 Dose 5 (Single)
A single dose of LP-005 (Dose 5) was administered intravenously.
LP-005 Dose 6 (Single)
A single dose of LP-005 (Dose 6) was administered intravenously.
Placebo (Single)
A single dose of placebo was administered intravenously.
LP-005 Dose 7 (Multiple)
LP-005 (Dose 7) was administered multiple times intravenously.
LP-005 Dose 8 (Multiple)
LP-005 (Dose 8) was administered multiple times intravenously.
LP-005 Dose 9 (Multiple)
LP-005 (Dose 9) was administered multiple times intravenously.
Placebo (Multiple)
Placebo was administered multiple times intravenously.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male subjects with a weight of ≥50 kg, female subjects with a weight of ≥45 kg, and BMI between 19.0 and 26.0 kg/m² (inclusive).
3. Vaccination: Meningococcal Conjugate Vaccine, Serogroups A, C, W, Y (MPV-ACYW) meningococcal conjugate vaccine and Streptococcus pneumoniae vaccine should be given 14 days or more before randomisation.
4. Male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical contraceptive methods (such as total abstinence, condoms, Iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs.
5. The subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the informed consent.
6. The subjects were able to communicate well with the researchers and complete the study according to the protocol.
Exclusion Criteria
2. Any history of Neisseria gonorrhea, meningitis infection, and Guillain-Barré syndrome.
3. Contraindications to meningococcal vaccination (previous medical history such as epilepsy or other brain disorders).
4. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection, including herpes, shingles, or cold sores, within 14 days prior to screening.
5. History of unexplained recurrent infections, or use of systemic antibiotics within 90 days prior to dosing.
6. Malignancy or history of malignancy, except non-melanoma skin cancer cured for more than 3 years.
7. Positive HIV test (HIV-Ab), positive hepatitis B virus (HBV) test (HBsAg), positive hepatitis C virus (HCV), positive anti-syphilis helix-specific antibodies.
8. Participation in a clinical trial of any other drug within 3 months prior to screening or within 5 half-lives of other clinical trial drugs (selecting the longer time period).
9. Women who are pregnant, breastfeeding, or at risk of pregnancy.
10. Any condition deemed unsuitable for study participation by the investigator.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Longbio Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P10-LP005-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.